Peer-reviewed veterinary case report
Oclacitinib treatment for pemphigus skin diseases in dogs
By Breanna L. Scranton et al.·Published in Veterinary dermatology (Print)·2026·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases
- Species:
- dog
Plain-English summary
A group of 21 dogs with skin conditions called pemphigus foliaceus, pemphigus vulgaris, or mucous membrane pemphigoid were treated with a medication called oclacitinib (Apoquel). This treatment helped some dogs reduce their need for steroids, with eight out of 18 dogs with pemphigus foliaceus showing improvement, including five reaching full remission. One dog with pemphigus vulgaris and another with mucous membrane pemphigoid also achieved remission with oclacitinib. While it worked well for some, it was not effective for all, and the long-term safety of higher doses is still uncertain.
People also search for: dog skin problems treatment · pemphigus foliaceus in dogs · oclacitinib for dog skin conditions
Abstract
This study was performed to retrospectively evaluate the efficacy of oclacitinib (OC) (Apoquel; Zoetis) as a treatment option for pemphigus foliaceus (PF), pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP). To determine if OC can reduce or replace the corticosteroid use in dogs with PF, PV and MMP. There were no animal subjects. Multicentre retrospective study reviewing medical records from two institutions for dogs diagnosed with PF, PV or MMP and prescribed OC between 2014 and 2025. Twenty‐one dogs diagnosed with PF, PV or MMP via histopathological results were included. OC alone was effective in eight of 18 PF dogs at a median dose of 0.65 mg/kg/day per os (range 0.5–1.9 mg/kg/day p.o.). Five dogs reached clinical remission, and three reached partial remission. One PV dog and the MMP dog each reached clinical remission with OC alone at 0.7 mg/kg/day and 0.24 mg/kg every other day, respectively. OC was a corticosteroid‐sparing agent or adjunctive therapy in seven of 18 PF dogs at a median dose of 0.6 mg/kg/day (range 0.4–2.4 mg/kg/day). One PV dog reached partial remission at OC 1.9 mg/kg/day and prednisone 1.8 mg/kg/day yet died from pancreatitis. OC was ineffective in three of 18 PF dogs at a median dose of 1.0 mg/kg/day p.o. (range 0.9–1.2 mg/kg/day p.o.). Statistical significance was not analysed. OC is an effective sole therapeutic agent or adjunctive therapy in a subset of dogs with PF, PV or MMP. The long‐term safety of higher doses of OC is unknown.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/044718fb8aadb81aaf55547442380b6b96eaa037